超越血管内皮生长因子轴：肿瘤非抗血管生成分子靶向治疗中影像学作用的最新进展。
Beyond the vascular endothelial growth factor axis: update on role of imaging in nonantiangiogenic molecular targeted therapies in oncology.
机构信息
1 Department of Imaging, Dana-Farber Cancer Institute and Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, 450 Brookline Ave, Boston, MA 02215.
出版信息
AJR Am J Roentgenol. 2015 May;204(5):919-32. doi: 10.2214/AJR.14.12876.
OBJECTIVE
This article provides a comprehensive review of molecular targeted therapies that do not act directly through vascular endothelial growth factor pathways, highlighting the role of imaging in assessment of treatment response and drug toxicities.
CONCLUSION
A substantial number of molecular targeted therapies act on nonantiangiogenic pathways. Familiarity with these drugs, their personalized tumor response criteria, and class- and drug-specific toxicities will help radiologists to be an integral part of the multi-disciplinary oncology team.
目的
本文全面回顾了不直接通过血管内皮生长因子途径发挥作用的分子靶向治疗药物，重点介绍了影像学在评估治疗反应和药物毒性方面的作用。
结论
大量的分子靶向治疗药物作用于非抗血管生成途径。熟悉这些药物、其个体化肿瘤反应标准以及药物的类别和特异性毒性将有助于放射科医生成为多学科肿瘤团队的重要组成部分。
Zotero 插件